CLAIM DESK / FREQUENT QUESTIONS
Questions, With the Evidence Boundary Included
Direct answers that identify the model, endpoint, and limit instead of stretching a finding past its source.
What is KPV peptide?
KPV is the three-amino-acid sequence lysine-proline-valine, the C-terminal fragment of alpha-melanocyte-stimulating hormone. It retains anti-inflammatory activity in preclinical research without the pigment-forming action of the full hormone [5]. It is not an approved medicine, and the cited evidence does not include human clinical trials.
What does KPV peptide do?
In intestinal cells and mouse models, KPV enters epithelial cells through the PepT1 transporter and reduces NF-kB and MAP-kinase inflammatory signaling and pro-inflammatory cytokine secretion [3]. Other animal work suggests a distinct route involving IL-1beta rather than conventional melanocortin receptors [7]. These are mechanistic and preclinical findings.
What is KPV peptide used for in research?
The clearest research program concerns experimental inflammation, especially mouse models of colitis and targeted delivery to inflamed colon tissue [1][2][3][4]. Rabbit work has also examined corneal epithelial wound healing [6]. These models identify possible mechanisms and formulation strategies; they do not establish a human therapeutic use.
What is semaglutide?
Semaglutide is a modified GLP-1 receptor agonist peptide and an approved prescription medicine in manufactured formulations. It affects glucose-dependent insulin signaling, glucagon release, gastric emptying, and appetite circuits. Its record includes large randomized trials measuring weight, cardiovascular, and kidney outcomes [9][10][11].
What is semaglutide used for?
Approved indications depend on formulation and regulatory labeling. In the cited research, semaglutide was studied for weight management in adults with overweight or obesity [11], cardiovascular-event reduction in adults with established cardiovascular disease and overweight or obesity [10], and kidney outcomes in adults with type 2 diabetes and chronic kidney disease [9]. This is research context, not individual advice.
How does semaglutide work for weight loss?
Semaglutide activates GLP-1 receptors involved in satiety and meal termination, reduces food intake, and slows gastric emptying. STEP 1 reported a mean body-weight change of -14.9% with semaglutide versus -2.4% with placebo at 68 weeks [11]. Those are trial-group averages under a protocol, not a guaranteed personal result.
What is CJC-1295?
CJC-1295 is a modified analogue of growth-hormone-releasing hormone. The long-acting DAC form binds albumin, extending exposure. Small human studies found sustained increases in growth hormone and IGF-1 while preserving pulsatile secretion [16][17]. It is not an approved human medicine, and broad wellness claims are not established by those studies.
Is CJC-1295 safe?
The cited record is not sufficient to establish long-term safety. Human studies were small and designed mainly to describe pharmacology [15][16][17]. Sustained GH/IGF-1 stimulation creates mechanism-based questions about fluid balance and glucose regulation. Community reports remain anecdotal, not clinical evidence, and uncertain product identity adds a separate risk [14].
How much CJC-1295 should a person take?
Right Peptides does not provide human dosing. CJC-1295 is not approved for human use, and protocols circulated outside controlled research are not validated by the cited evidence. Quantities reported in early studies describe experimental conditions [16][17]; they are not recommendations and should not be repurposed as instructions.
What is NAD+ used for in research?
NAD+ is a coenzyme central to cellular redox metabolism and a substrate for sirtuins, PARPs, and CD38-related signaling [21]. Human supplementation studies mainly test precursors such as NMN and NR, measuring blood NAD+, insulin sensitivity, walking performance, or related intermediate outcomes [19][20][22].
What is the downside of NAD+ claims?
The main interpretive downside is overreach. Raising blood NAD+ does not by itself prove a tissue effect, disease prevention, or longer life. A current review finds that human efficacy is limited and tissue-specific data are sparse [18]. Intact NAD+, NMN, NR, and compounded intravenous preparations also should not be treated as interchangeable.
Is it safe to take NAD daily?
That question cannot be answered generally from this source set. Short human trials of NMN and NR reported tolerability under their specific protocols [19][22], but they do not establish long-term safety for every population, route, product, or amount. This digest does not make individual-use recommendations.